

**Registered Number 03357249**

**MAELOR LABORATORIES LIMITED**

**Abbreviated Accounts**

**30 June 2015**

## Abbreviated Balance Sheet as at 30 June 2015

	<i>Notes</i>	<i>2015</i>	<i>2014</i>
		£	£
<b>Called up share capital not paid</b>		-	-
<b>Fixed assets</b>			
Intangible assets		-	-
Tangible assets		-	-
Investments		-	-
		<u>-</u>	<u>-</u>
<b>Current assets</b>			
Stocks		-	-
Debtors		-	-
Investments		-	-
Cash at bank and in hand		2	2
		<u>2</u>	<u>2</u>
<b>Prepayments and accrued income</b>		-	-
<b>Creditors: amounts falling due within one year</b>		0	0
<b>Net current assets (liabilities)</b>		<u>2</u>	<u>2</u>
<b>Total assets less current liabilities</b>		<u>2</u>	<u>2</u>
<b>Creditors: amounts falling due after more than one year</b>		0	0
<b>Provisions for liabilities</b>		0	0
<b>Accruals and deferred income</b>		0	0
<b>Total net assets (liabilities)</b>		<u>2</u>	<u>2</u>
<b>Capital and reserves</b>			
Called up share capital		2	2
Share premium account		0	0
Revaluation reserve		0	0
Other reserves		0	0
Profit and loss account		0	0
<b>Shareholders' funds</b>		<u>2</u>	<u>2</u>

- For the year ending 30 June 2015 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 31 March 2016

And signed on their behalf by:

**Andrew Timothy Franklin, Director**

**Notes to the Abbreviated Accounts for the period ended 30 June 2015****1 Accounting Policies****Basis of measurement and preparation of accounts**

1. The financial statements have been prepared under the historical cost convention and in accordance with applicable accounting standards.

2. The company did not trade during the year, therefore there are no transactions on the profit and loss account.

3. The company is a subsidiary undertaking of IS Pharma Ltd which is the immediate holding company. IS Pharma Ltd is a subsidiary of Sinclair Pharma Holdings Ltd, which is a subsidiary of Sinclair IS Pharma plc. All companies are incorporated in England. Sinclair IS Pharma plc is the ultimate parent company by virtue of its controlling interest in the share capital of Sinclair Pharma Holdings Ltd. Sinclair IS Pharma plc is preparing group accounts including the group financial statements of IS Pharma Ltd and Sinclair Pharma Holdings Ltd.

**4. Post balance sheet events**

On 10 December 2015, the Company entered into a framework agreement with Sinclair IS Pharma plc, under which various businesses and assets of certain pharmaceutical and medical device products were transferred to the Company as part of a Group restructuring. Under the framework agreement, the total consideration for the transfer of the business and assets was £59,700,000 which was satisfied by the issue of interest bearing promissory notes to each transferring company. Following the transfer of these businesses and assets the Company began trading on 10 December 2015.

On 17 December 2015, the Company was sold to Alliance Pharmaceuticals Limited, which became the immediate parent undertaking, as part of the disposal of the Sinclair IS Pharma plc's non-aesthetics business. This resulted in the sale by each former group undertaking of their promissory notes to Alliance Pharmaceuticals Limited for cash consideration of £59,700,000. Alliance Pharmaceuticals Limited is a subsidiary of Alliance Pharma plc, which became the ultimate parent undertaking.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.